Inhibrx Biosciences Inc
Research Inhibrx Biosciences Inc (INBX) on Bullrun: market cap USD 1.81B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINBX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.81B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 33.44M
- Free cash flow-USD 38.03M
Valuation Snapshot
latest market cap is USD 1.81B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.30M | -USD 140.06M | -USD 129.83M | n/a | -9.04 | USD 124.22M | USD 100.56M | USD 7.99M |
| FY2024 | USD 200.00K | USD 1.69B | -USD 197.01M | n/a | 112.62 | USD 152.60M | USD 0 | USD 133.58M |
| FY2023 | USD 1.80M | -USD 241.36M | -USD 197.90M | n/a | -20.48 | USD 277.92M | USD 206.97M | USD 43.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.81B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.15B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 222.93M | 0.1 | n/a | n/a |
About Inhibrx Biosciences Inc
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Inhibrx Biosciences Inc's market cap?
Inhibrx Biosciences Inc's market capitalization is USD 1.81B.
What does Inhibrx Biosciences Inc do?
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.